ADVANCED PROSTATE CANCER: WHAT YOU NEED TO KNOW ABOUT TREATMENT AND RESEARCH



EVOLVE Program Resource Guide

Understanding Your Treatment Plan | Questions to Ask Your Doctor

- What are my standard-of-care treatment options?
- Is there a clinical trial that may be right for me?
- Are there radiation therapy or surgical options?
- Are there chemotherapy-sparing options?
- How is the treatment administered, and where will I receive the therapy?
- Who should I call if something happens on the weekend or on a holiday?

Clinical Trial Phases

Phase I: The goal is to test the safety of the drug, finding the appropriate dose that produces the fewest side effects.

Phase II: Further assesses the safety of the drug and the effectiveness of the treatment.Phase III: Compares the efficacy of the new treatment to the standard-of-care treatment.Phase IV: Study that looks at drugs that have already been approved to get additional safety information and to learn more about long-term benefits and side effects.

What Is Shared Decison-Making?

Process of communication by which patients and clinicians collaborate to make healthcare decisions. The process encourages patients to take a more active role in their care and treatment.

Glossary

Biomarker Testing (molecular testing): Laboratory testing that identifies certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. In cancer, it may also be used to evaluate treatment or to make a prognosis.

BRCA 1, BRCA 2: Inherited mutated genes linked to hereditary prostate cancer.

Germline Mutations: A hereditary mutation, passed directly from a parent to a child at the time of conception. Cancer caused by germline mutations is called inherited cancer and accounts for about 5% to 20% of all cancers.

Homologous Recombination Repair (HRR) Pathway: A pathway that is frequently mutated in men with advanced prostate cancer.

Immunotherapy: Type of therapy that harnesses one's own immune system to help the body fight cancer, infection, and other diseases.

PARP Inhibitors: A type of targeted treatment that inhibits the enzyme poly (ADP-ribose) polymerase.

PSMA PET Scan: An imaging test that is used to detect prostate cancer anywhere in the body.

Somatic Mutation: Mutations that can occur in any of the cells of the body but are not hereditary. These mutations may, in some cases, cause cancer or other diseases.

EV@LVE

Evolve Prostate Cancer is brought to you by the Patient Empowerment Network. It is sponsored by Janssen Oncology and Legend Biotech, Parexel, and through generous donations from people like you.

www.powerfulpatients.org